Literature DB >> 16984981

Serum adiponectin and coronary heart disease risk in older Black and White Americans.

Alka M Kanaya1, Christina Wassel Fyr, Eric Vittinghoff, Peter J Havel, Matteo Cesari, Barbara Nicklas, Tamara Harris, Anne B Newman, Suzanne Satterfield, Steve R Cummings.   

Abstract

CONTEXT: Adiponectin may influence the risk of coronary heart disease (CHD) independently of traditional cardiovascular risk factors.
OBJECTIVE: Because body composition and adiponectin levels vary by race, we examined the relationship of adiponectin with prevalent and incident CHD in a cohort of older Black and White adults. DESIGN AND
SETTING: We conducted a cross-sectional and prospective cohort study at two U.S. clinical centers. PARTICIPANTS: Participants included 3075 well-functioning adults between ages 70 and 79 yr enrolled in the Health, Aging, and Body Composition study. MAIN OUTCOME MEASURES: Prevalent CHD was defined as history of myocardial infarction, coronary artery bypass graft, percutaneous coronary transluminal angioplasty, angina, or major electrocardiogram abnormalities. After excluding those with prevalent CHD, incident CHD was defined as hospitalized myocardial infarction or CHD death.
RESULTS: At baseline, 602 participants (19.6%) had CHD. During 6 yr of follow-up, 262 (10.6%) incident CHD events occurred. Whites had higher median adiponectin than Blacks (12 vs. 8 microg/ml, P < 0.001). Race modified the effect of adiponectin (P for interaction was 0.002 for prevalent CHD, and P = 0.02 for incident CHD). Among Whites, an inverse association of adiponectin with CHD was explained by high-density lipoprotein and glucose. Among Blacks, a doubling of adiponectin was associated with a 40% higher risk of both prevalent CHD (odds ratio, 1.41; 95% confidence interval, 1.11-1.78) and incident CHD (hazards ratio, 1.37; 95% confidence interval, 1.01-1.87) after adjusting for explanatory variables.
CONCLUSION: High circulating concentrations of adiponectin were associated with higher risk of CHD in older Blacks, even accounting for traditional CHD risk factors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16984981     DOI: 10.1210/jc.2006-0107

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  31 in total

1.  Effects of adiponectin deficiency on structural and metabolic remodeling in mice subjected to pressure overload.

Authors:  Karen M O'Shea; David J Chess; Ramzi J Khairallah; Sharad Rastogi; Peter A Hecker; Hani N Sabbah; Kenneth Walsh; William C Stanley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-03-26       Impact factor: 4.733

2.  Variants in the adiponectin gene and serum adiponectin: the Coronary Artery Development in Young Adults (CARDIA) Study.

Authors:  Christina L Wassel; James S Pankow; David R Jacobs; Michael W Steffes; Na Li; Pamela J Schreiner
Journal:  Obesity (Silver Spring)       Date:  2010-04-15       Impact factor: 5.002

3.  Adipokines and the risk of fracture in older adults.

Authors:  Kamil E Barbour; Joseph M Zmuda; Robert Boudreau; Elsa S Strotmeyer; Mara J Horwitz; Rhobert W Evans; Alka M Kanaya; Tamara B Harris; Douglas C Bauer; Jane A Cauley
Journal:  J Bone Miner Res       Date:  2011-07       Impact factor: 6.741

4.  ADIPOQ polymorphisms, monounsaturated fatty acids, and obesity risk: the GOLDN study.

Authors:  Daruneewan Warodomwichit; Jian Shen; Donna K Arnett; Michael Y Tsai; Edmond K Kabagambe; James M Peacock; James E Hixson; Robert J Straka; Michael A Province; Ping An; Chao-Qiang Lai; Laurence D Parnell; Ingrid B Borecki; Jose M Ordovas
Journal:  Obesity (Silver Spring)       Date:  2008-12-18       Impact factor: 5.002

Review 5.  Role of adipocytokines in predicting the development of diabetes and its late complications.

Authors:  Nese Ersoz Gulcelik; Aydan Usman; Alper Gürlek
Journal:  Endocrine       Date:  2009-09-25       Impact factor: 3.633

6.  Adiponectin and risk of vascular events in the Northern Manhattan study.

Authors:  Hannah Gardener; Ronald Goldberg; Armando J Mendez; Clinton B Wright; Tatjana Rundek; Mitchell S V Elkind; Ralph L Sacco
Journal:  Atherosclerosis       Date:  2012-11-28       Impact factor: 5.162

7.  Relationships between plasma adiponectin and body fat distribution, insulin sensitivity, and plasma lipoproteins in Alaskan Yup'ik Eskimos: the Center for Alaska Native Health Research study.

Authors:  Anna V Goropashnaya; Johanna Herron; Mary Sexton; Peter J Havel; Kimber L Stanhope; Rosemarie Plaetke; Gerald V Mohatt; Bert B Boyer
Journal:  Metabolism       Date:  2009-01       Impact factor: 8.694

8.  Genetic variation in adiponectin (ADIPOQ) and the type 1 receptor (ADIPOR1), obesity and prostate cancer in African Americans.

Authors:  J L Beebe-Dimmer; K A Zuhlke; A M Ray; E M Lange; K A Cooney
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-08-10       Impact factor: 5.554

9.  Adiponectin and risk of coronary heart disease in older men and women.

Authors:  Jorge R Kizer; Joshua I Barzilay; Lewis H Kuller; John S Gottdiener
Journal:  J Clin Endocrinol Metab       Date:  2008-07-01       Impact factor: 5.958

10.  Is adiponectin associated with acute myocardial infarction in Iranian non obese patients?

Authors:  Mohammad Shojaie; Abdoreza Sotoodah; Ghafar Shafaie
Journal:  Lipids Health Dis       Date:  2009-05-28       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.